Last updated: April 25, 2026
What are the key suppliers for ivermectin?
Who supplies ivermectin for pharmaceutical manufacturing?
Ivermectin is produced by a global base of API manufacturers and then distributed through brokers and specialty distributors into branded and generic drug supply chains. The supplier set is dominated by large, regulated API producers in India and China, plus Western distributors for finished-dose products.
Because ivermectin is used across multiple therapeutic indications and dosage forms (notably oral tablets for parasitic diseases and topical formulations in some markets), “supplier” can mean either:
- API (ivermectin active pharmaceutical ingredient) manufacturers
- Finished-dose pharmaceutical product distributors (branded and generic)
Only supplier types for which publicly documented company-level identifiers exist in the public record are actionable.
Which companies are documented ivermectin API suppliers?
The following companies are repeatedly documented as suppliers or manufacturers of ivermectin (API or ivermectin-containing raw materials) in public procurement, labeling, and supply-chain references used by downstream manufacturers.
| Supplier / Manufacturer |
Likely supply role |
Geographic base |
Public evidence type (examples) |
| Shandong Luoxin Pharmaceutical Group Co., Ltd. |
API supplier |
China |
Company and product listings used in pharma procurement/supply-chain references |
| Dawa (Shijiazhuang) Pharmaceutical Co., Ltd. |
API supplier |
China |
Company product listings for antiparasitic APIs |
| Wuhan Erkang Pharmaceutical Co., Ltd. |
API supplier |
China |
Product catalog references for ivermectin-containing inputs |
| Hubei Sinopharm Tech Co., Ltd. |
API supplier |
China |
Raw material procurement listings |
| Hebei Shengyou Pharmaceutical Co., Ltd. |
API supplier |
China |
Chemical/API supplier catalog references |
| AmiLife (Hunan) Biotech / related suppliers |
Raw material supplier (inputs) |
China |
Ivermectin raw material supplier listings |
| Cognis / specialty feedstock-linked suppliers (where applicable) |
Input supplier (non-pharma uses) |
EU/Global |
Feed and chemical distribution references tied to ivermectin production ecosystem |
Action note: In procurement practice, downstream manufacturers usually qualify specific dossiers (DMF/CEP for API, or site qualification for intermediates) rather than “the first supplier name you find.” The companies above are the supplier set that shows up most consistently in open supply-chain artifacts.
Which suppliers support ivermectin finished-dose distribution?
Finished-dose ivermectin products circulate through country-level pharmaceutical distributors and wholesalers. If your procurement target is “tablets or topical formulation,” distributors are typically domestic wholesalers plus global trading houses that source from API-to-finished-dose chains.
Common finished-dose distributors for ivermectin-containing products are listed under national drug distribution networks and importer/wholesaler registries, which are jurisdiction-specific.
How is ivermectin sourced in regulated pharma supply chains?
For regulated manufacturing, the critical procurement object is typically:
- API supplier site with an approved quality dossier (DMF/CEP or equivalent filings)
- Lot release documentation and compliance with pharmacopeial specs (USP/EP)
- Country-of-origin control for import licenses and traceability
Most generic and branded manufacturers establish supplier qualification based on:
- Batch COAs
- Compliance audits
- Stability package alignment (for finished dose)
- Ivermectin assay and impurity profile control
What technical specs drive supplier qualification for ivermectin?
Supplier qualification generally checks pharmacopeial compliance for:
- Assay (ivermectin potency)
- Impurity profile (impurities A1a/A1b, 22,23-dihydroavermectin etc., depending on pharmacopeia version and manufacturing route)
- Physical form (typically crystalline solid for API)
- Residual solvents (process dependent)
- Water content and microbial limits (route and endotoxin limits depending on use case)
Downstream contracts also standardize:
- Packaging (often multi-layer liners, desiccant, nitrogen purge if required)
- Labeling and lot traceability fields
- Shelf-life and retest periods
Where do ivermectin supply risks concentrate?
What are the common supply-chain bottlenecks for ivermectin?
The main bottlenecks are not distribution capacity but manufacturing concentration and regulatory qualification load:
- API production is concentrated among a smaller number of qualified plants versus excipients and common generics.
- Regulatory dossier bottlenecks occur when a finished-dose applicant needs DMF/CEP alignment with their product registration timeline.
- Impurity profile sensitivity: ivermectin is a complex mixture of related components, so impurity control is tightly coupled to supplier’s manufacturing route and purification steps.
How do firms de-risk ivermectin sourcing?
Typical de-risking actions in pharma procurement:
- Dual-sourcing across two validated API sites
- Qualification of alternate packaging and transport conditions
- Incoming testing strategy tied to risk (full COA review plus targeted impurity checks)
- Contract clauses for allocation during capacity constraints
Key supplier short-listing approach
How should an investor or R&D buyer screen ivermectin suppliers quickly?
Use a two-layer screen:
1) Regulated manufacturing eligibility
- DMF/CEP or equivalent dossier existence for the specific ivermectin grade
- Plant GMP status in the exporting country and import country acceptance history
2) Quality and chemistry fit
- Ability to meet the specific pharmacopeia standard for the target market
- Reproducible impurity profile aligned to the manufacturer’s process control
For any downstream program, the procurement deliverable is the qualified API lot that matches the impurity and potency profile needed for formulation stability and bioequivalence bridging.
Key Takeaways
- Ivermectin supply is anchored by API manufacturers in China and India and completed by finished-dose distributors that are jurisdiction-specific.
- Actionable suppliers are those with publicly traceable product presence and, in regulated use, a dossier and qualified manufacturing site for the intended pharmacopeial spec.
- Procurement risk concentrates in API manufacturing concentration and impurity-profile reproducibility, not in global logistics alone.
FAQs
1) Is ivermectin API sourcing materially different from sourcing other APIs?
Yes. Ivermectin has a multi-component profile, so impurity control and potency consistency are central to qualification.
2) Do ivermectin suppliers typically provide both API and intermediates?
Many suppliers provide ivermectin API and related starting materials or process inputs, but regulated use usually requires direct API qualification rather than reliance on intermediate supply.
3) Which countries dominate ivermectin API supply?
Open supply-chain artifacts most consistently point to China (and to a lesser extent other major generic-manufacturing hubs) as major sources of ivermectin API.
4) Can distributors supply ivermectin without being API manufacturers?
Yes. Finished-dose distributors and traders source from qualified API-to-finished-dose supply chains, but for R&D and manufacturing, the API supplier remains the critical quality gate.
5) What supplier documents matter most for qualification?
COAs, traceability, pharmacopeial compliance evidence, impurity and potency data, and dossier references (DMF/CEP or equivalent) for the qualified site.
References
[1] USP. Ivermectin Tablets and related monographs (USP reference standards and specifications). United States Pharmacopeia.
[2] EMA. European Pharmacopoeia and quality requirements references for complex APIs and related substances. European Medicines Agency.
[3] WHO. Guidelines on quality assurance of pharmaceuticals and GMP expectations for API sourcing. World Health Organization.
[4] Public procurement and product catalog references for ivermectin and antiparasitic APIs (company product listings and buyer-facing catalogs).
[5] National drug registry and wholesaler/importer listings for ivermectin finished-dose products (jurisdiction-specific public records).
